Calidi Biotherapeutics, Inc. (CLDI)
(Real Time Quote from BATS)
$6.95 USD
+6.36 (1,071.81%)
Updated Aug 5, 2025 12:26 PM ET
4-Sell of 5 4
F Value F Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CLDI 6.95 +6.36(1,071.81%)
Will CLDI be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CLDI based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CLDI
Calidi Biotherapeutics, Inc. (CLDI) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
CLDI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for CLDI
CLDI Trading Halted Due to Volatility Pause
Calidi Biotherapeutics (CLDI) Resumes Trading: Key Insights for Investors
Calidi Biotherapeutics Inc trading resumes
Calidi Biotherapeutics Inc trading halted, volatility trading pause
12 Health Care Stocks Moving In Tuesday's Intraday Session